Stealth BioTherapeutics discloses FDA rejection letter in effort to rally support

Taking stock of the drug industry, from the lab to the medicine chest

August 18, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Stealth BioTherapeutics discloses FDA rejection letter in effort to rally support for rare disease drug The company is hopeful that its therapy for Barth syndrome, seen as a test case for agency approval standards, will still get green light. By Ed Silverman STAT+ | Conflicts among CDC and FDA vaccine panel members are not as numerous as you think, study finds "The patterns we're seeing don't seem particularly worrisome" said Genevieve Kanter, a study author and senior scholar at the Schaeffer Center. By Ed Silverman STAT+ | Health care CEOs harvest billions even as industry lags broader stock market Annual executive compensation review of prominent health care companies found 275 CEOs earning $3.6 billion in 2024. By Bob Herman and J. Emory Parker adobe Opinion: Former CDC Director William Foege: How public health can fight back in a time of dangerous nonsense William Foege helped eradicate smallpox. Now, he says, public health faces an equally devastating threat from Robert F. Kennedy Jr. By William Foege

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser